% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Veinalde:241158,
      author       = {R. Veinalde$^*$ and G. Pidelaserra-Martí$^*$ and C. Moulin
                      and C. L. Tan$^*$ and T. Schäfer$^*$ and N. Kang and C. R.
                      Ball and J. Leichsenring and A. Stenzinger and L. Kaderali
                      and D. Jäger$^*$ and G. Ungerechts$^*$ and C. Engeland$^*$},
      title        = {{V}irotherapy combined with anti-{PD}-1 transiently
                      reshapes the tumor immune environment and induces anti-tumor
                      immunity in a preclinical {PDAC} model.},
      journal      = {Frontiers in immunology},
      volume       = {13},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-00266},
      pages        = {1096162},
      year         = {2023},
      note         = {#EA:F230#LA:F230#},
      abstract     = {Pancreatic ductal adenocarcinoma (PDAC) is largely
                      refractory to cancer immunotherapy with PD-1 immune
                      checkpoint blockade (ICB). Oncolytic virotherapy has been
                      shown to synergize with ICB. In this work, we investigated
                      the combination of anti-PD-1 and oncolytic measles vaccine
                      in an immunocompetent transplantable PDAC mouse model.We
                      characterized tumor-infiltrating T cells by
                      immunohistochemistry, flow cytometry and T cell receptor
                      sequencing. Further, we performed gene expression profiling
                      of tumor samples at baseline, after treatment, and when
                      tumors progressed. Moreover, we analyzed systemic anti-tumor
                      and anti-viral immunity.Combination treatment significantly
                      prolonged survival compared to monotherapies.
                      Tumor-infiltrating immune cells were increased after
                      virotherapy. Gene expression profiling revealed a unique,
                      but transient signature of immune activation after
                      combination treatment. However, systemic anti-tumor immunity
                      was induced by virotherapy and remained detectable even when
                      tumors progressed. Anti-PD-1 treatment did not impact
                      anti-viral immunity.Our results indicate that combined
                      virotherapy and ICB induces anti-tumor immunity and reshapes
                      the tumor immune environment. However, further refinement of
                      this approach may be required to develop its full potential
                      and achieve durable efficacy.},
      keywords     = {Mice / Animals / Pancreatic Neoplasms: pathology /
                      Carcinoma, Pancreatic Ductal: genetics / Immunotherapy:
                      methods / Oncolytic Virotherapy: methods / PD-1 (Other) /
                      PDAC (Other) / cancer immunotherapy (Other) / immune
                      checkpoint (Other) / measles vaccine (Other) / oncolytic
                      virus (Other)},
      cin          = {F230 / D170 / D120},
      ddc          = {610},
      cid          = {I:(DE-He78)F230-20160331 / I:(DE-He78)D170-20160331 /
                      I:(DE-He78)D120-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36726983},
      pmc          = {pmc:PMC9886093},
      doi          = {10.3389/fimmu.2022.1096162},
      url          = {https://inrepo02.dkfz.de/record/241158},
}